SSS17
Phase 2Small molecule
SSS17 is one of 72 small molecule programs targeting Anemia. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Anemia
#DrugCompanyPhaseTrials
1Reblozyl
Bristol-Myers SquibbApproved
Zemplar
AbbVieApproved
Injectafer
AAmerican Regent, Inc.
Approved
Nipent
PfizerApproved
Retin-a
VValeant Pharmaceuticals
Approved
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Aldactone
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anemia2 trials
Phase 12 trials
Tics1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSS17. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details